Karim Mowla1, Elham Rajai1, Ali Ghorbani2, Mehrdad Dargahi-Malamir3, Mohammad Bahadoram4, Shooka Mohammadi5. 1. Faculty, Department of Rheumatology, Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran . 2. Faculty, Department of Nephrology, Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran . 3. Faculty, Department of Internal Medicine, Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran . 4. Medical Student Research Committee, Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran . 5. Dietetics and Nutritional Sciences Programmes, School of Healthcare Sciences, Faculty of Health Sciences, Universiti Kebangsaan Malaysia , Kuala Lumpur, Malaysia .
Abstract
INTRODUCTION:HMG-CoA (3-hydroxy-3- methylglutary lcoenzyme A) reductase inhibitors (statins) have anti-inflammatory properties which may be particularly useful in rheumatoid arthritis to suppress disease activity and inflammatory factors. AIM: The purpose of this clinical trial was to determine anti-inflammatory properties of statins in rheumatoid arthritis. MATERIALS AND METHODS:Eighty Iranian patients with rheumatoid arthritis, aged between 19 to 75 years were recruited to take part in this randomized, double-blind placebo-controlled trial. Subjects were randomly allocated to two groups to take atorvastatin or placebo 40 mg daily as an adjunct to current disease-modifying anti-rheumatic drugs (DMARDs) treatment. Disease Activity Score-28 (DAS28), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), swollen joint count (SJC) & tender joint count (TJC) were assessed before and after three months intervention. RESULTS: Analysis was based on intention to treat. DAS28 significantly declined in the atorvastatin group in comparison with placebo (p< 0.001). SJC, TJC, CRP and ESR also were significantly dropped in the atorvastatin group in comparison with placebo. CONCLUSION: It can be concluded that atorvastatin can suppress RA activity and inflmmatory factors in RA patients for high to moderate grade of inflmmation.
RCT Entities:
INTRODUCTION: HMG-CoA (3-hydroxy-3- methylglutary lcoenzyme A) reductase inhibitors (statins) have anti-inflammatory properties which may be particularly useful in rheumatoid arthritis to suppress disease activity and inflammatory factors. AIM: The purpose of this clinical trial was to determine anti-inflammatory properties of statins in rheumatoid arthritis. MATERIALS AND METHODS: Eighty Iranian patients with rheumatoid arthritis, aged between 19 to 75 years were recruited to take part in this randomized, double-blind placebo-controlled trial. Subjects were randomly allocated to two groups to take atorvastatin or placebo 40 mg daily as an adjunct to current disease-modifying anti-rheumatic drugs (DMARDs) treatment. Disease Activity Score-28 (DAS28), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), swollen joint count (SJC) & tender joint count (TJC) were assessed before and after three months intervention. RESULTS: Analysis was based on intention to treat. DAS28 significantly declined in the atorvastatin group in comparison with placebo (p< 0.001). SJC, TJC, CRP and ESR also were significantly dropped in the atorvastatin group in comparison with placebo. CONCLUSION: It can be concluded that atorvastatin can suppress RA activity and inflmmatory factors in RApatients for high to moderate grade of inflmmation.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker Journal: Ann Rheum Dis Date: 2010-09 Impact factor: 19.103
Authors: Bernard P Leung; Naveed Sattar; Anne Crilly; Morag Prach; David W McCarey; Helen Payne; Rajan Madhok; Carol Campbell; J Alastair Gracie; Foo Y Liew; Iain B McInnes Journal: J Immunol Date: 2003-02-01 Impact factor: 5.422
Authors: David W McCarey; Iain B McInnes; Rajan Madhok; Rosie Hampson; Olga Scherbakov; Ian Ford; Hilary A Capell; Naveed Sattar Journal: Lancet Date: 2004-06-19 Impact factor: 79.321
Authors: Magaly Villafrádez-Díaz; Yesenia Santiago-Casas; Mariely Nieves-Plaza; Myraida Morales; Vanessa Rodríguez; Grissel Ríos; David Martínez; Luis M Vilá Journal: P R Health Sci J Date: 2014-03 Impact factor: 0.705
Authors: Madeline N Peterson; Hayley J Dykhoff; Cynthia S Crowson; John M Davis; Lindsey R Sangaralingham; Elena Myasoedova Journal: Arthritis Res Ther Date: 2021-09-18 Impact factor: 5.606
Authors: Cynthia Aranow; John Cush; Marcy B Bolster; Christopher C Striebich; Maria Dall'era; Meggan Mackay; Ewa Olech; Tracy Frech; Jane Box; Richard Keating; Mary Chester Wasko; William St Clair; Alan Kivitz; Weiquang Huang; PetaGay Ricketts; Beverly Welch; Sherrie Callahan; Meagan Spychala; Karen Boyle; Kate York; Lynette Keyes-Elstein; Ellen Goldmuntz; Betty Diamond; Anne Davidson Journal: Rheumatology (Oxford) Date: 2020-07-01 Impact factor: 7.580
Authors: Jonathan T Davies; Spencer F Delfino; Chad E Feinberg; Meghan F Johnson; Veronica L Nappi; Joshua T Olinger; Anthony P Schwab; Hollie I Swanson Journal: Lipid Insights Date: 2016-11-14
Authors: Abdallah A Abdelmaksoud; Philippe H Girerd; Erin M Garcia; J Paul Brooks; Lauren M Leftwich; Nihar U Sheth; Steven P Bradley; Myrna G Serrano; Jennifer M Fettweis; Bernice Huang; Jerome F Strauss; Gregory A Buck; Kimberly K Jefferson Journal: PLoS One Date: 2017-08-28 Impact factor: 3.240